Insmed Incorporated

INSM · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.5%

Institutions105.1%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	–	$363.71M	$305.21M	$245.36M	$188.46M	$164.41M	$136.47M	$9.84M	$0	–
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	–	$85.74M	$65.57M	$55.13M	$44.15M	$39.87M	$24.21M	$2.42M	–	–
Revenue left after subtracting the direct cost of producing goods or services — how efficiently the core business converts sales into profit before overhead.	–	–	–	–	–	–	$112.25M	–	–	–
Gross profit as a percentage of revenue.	–	–	–	–	–	–	82.3%	–	–	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$1.25B	-$878.25M	-$709.63M	-$457.32M	-$375.09M	-$265.23M	-$235.25M	-$307.34M	-$188.92M	-$173.40M
Operating income as a percentage of revenue.	–	-241.5%	-232.5%	-186.4%	-199.0%	-161.3%	-172.4%	-3124.9%	–	–
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$1.28B	-$913.77M	-$749.57M	-$481.53M	-$434.65M	-$294.09M	-$254.34M	-$324.28M	-$192.65M	-$176.27M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-6.42	$-5.57	$-5.34	$-3.91	$-3.88	$-3.01	$-3.01	$-4.22	$-2.00	$-2.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-6.42	$-5.57	$-5.34	$-3.91	$-3.88	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$510.40M	$555.00M	$482.40M	$1.07B	$716.80M	$532.80M	$487.40M	$495.10M	$381.17M	$162.59M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$2.26B	$2.03B	$1.33B	$1.66B	$1.24B	$796.15M	$742.30M	$604.56M	$462.05M	$237.96M
All of the company's interest-bearing borrowings, short and long term combined.	$540.96M	$1.10B	$1.16B	$1.13B	$566.59M	$356.32M	$335.94M	$316.56M	$55.57M	$54.79M
Everything the company owes — debt, unpaid bills, and other obligations.	$1.53B	$1.74B	$1.66B	$1.57B	$833.04M	$520.27M	$480.63M	$396.29M	$100.99M	$83.47M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$738.98M	$285.38M	-$331.92M	$87.95M	$410.47M	$275.88M	$261.67M	$208.27M	$361.06M	$154.48M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$935.01M	-$683.88M	-$536.25M	-$400.44M	-$363.30M	-$219.35M	-$250.65M	-$257.98M	-$159.62M	-$146.71M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$32.56M	$21.92M	$13.29M	$9.88M	$7.29M	$6.24M	$42.27M	$13.09M	$3.00M	$4.20M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$967.58M	-$705.80M	-$549.53M	-$410.32M	-$370.59M	-$225.59M	-$292.92M	-$271.07M	-$162.62M	-$150.91M

	You	Peer avg
P/E	–	46.0
Revenue Growth	+296.1%	+35.6%
ROE	-87.2%	-8.5%

Insmed Incorporated

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison